Eli Lilly ’s experimental drug helped patients lose up to 24% of their weight after almost a year, the highest reduction seen in the obesity treatment space to date, according to new mid-stage clinical trial results released Monday. The trial's researchers said average weight loss did not appear to plateau after 48 weeks, suggesting a longer study could show even more. Eli Lilly’s other obesity drug Mounjaro, which is approved for type 2 diabetes, has helped patients lose up to 21% of their weight in clinical trials. Novo Nordisk’ s Wegovy, cleared for weight loss, has shown up to 15% weight loss in trials. But Wegovy only mimics one hunger-regulating hormone called GLP-1, while Mounjaro mimics GLP-1 and another hormone called GIP.

---

Persons: Eli Lilly ’, Eli Lilly, Eli Lilly’s retatrutide, ” Michael Weintraub, Eli Lilly’s, Eli Lilly's retatrutide Organizations: NYU Langone Health, Novo Nordisk